RESUMO
A comparison was made between the image quality of a photon-counting CT (PCCT) and a dual-source CT (DSCT). The evaluation of image quality was performed using a Catphan CT phantom, and the physical metrics, such as the noise power spectrum and task transfer function, were measured for both PCCT and DSCT at three CT dose indices (1, 5 and 10 mGy). Polyenergetic and virtual monoenergetic reconstructions were used to evaluate the performance differences by simulating a Gaussian spot with a radius of 5 mm and calculating the detectability index. The highest iterative reconstruction level was able to decrease the noise by about 70% compared with the filtered back projection using a parenchyma reconstruction kernel. The PCCT task transfer functions remained constant, while those of the DSCT increased with the reconstruction strength level. At monoenergetic 70 keV, a 50% decrease in noise was observed for DSCT with image smoothing, while PCCT had the same 50% decrease in noise without any smoothing. The PCCT detectability index at a reconstruction strength level of two was equivalent to the highest level of ADMIRE 5 for DSCT. The PCCT showed its superiority over the DSCT, especially for lung nodule detection.
RESUMO
Emphysema is a chronic respiratory disorder characterized by destruction of alveoli, usually due to cigarette smoking or exposure to noxious particles or gases. Dysfunction of proteins that are involved in lung development and maintenance, such as alpha-1 antitrypsin, also contributes to emphysema. Filamin A (FLNA) is an actin-binding protein involved in cytoskeleton reorganization. Mutations in the FLNA gene classically lead to abnormal neuronal migration and connective and vascular tissue anomalies. Pulmonary manifestations consist of a wide range of pulmonary disorders that occur during infancy. We report the first familial case of emphysema in non- and very low-smoking adults who carry a loss-of-function mutation of the FLNA gene. The identification of this new risk factor for emphysema encourages (1) screening, prevention and monitoring of pulmonary disorders in patients with FLNA mutation and (2) screening for FLNA mutation in patients with early-onset emphysema that is associated with low-smoking or vascular or connective tissue anomalies.
